Skip to main content

Advertisement

Table 2 Summary statistics of decreases from baseline in cerebrospinal fluid Aβ 1–42 following administration of GSK933776 a

From: Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I study

Sampling time (h) GSK933776 (n = 6/dose) Baselineb Postdosing Change (%) 95% CI
0 to 4 1 mg/kg 363.4 ± 60.1 350.2 ± 61.7 −3.6 (−10.8 to 3.6)
  3 mg/kg 479.2 ± 65.8 446.4 ± 70.8 −6.8 (−14.9 to 1.2)
  6 mg/kg 502.7 ± 71.1 456.1 ± 88.9 −9.7 (−15.4 to −3.9)
5 to 12 1 mg/kg 363.4 ± 60.1 333.9 ± 52.1 −7.9 (−12.6 to −3.2)
  3 mg/kg 479.2 ± 65.8 428.9 ± 77.1 −10.7 (−20.2 to −1.2)
  6 mg/kg 502.7 ± 71.1 433.5 ± 85.1 −14.2 (−19.8 to −8.6)
0 to 12 1 mg/kg 363.4 ± 60.1 340.6 ± 55.7 −6.2 (−11.2 to −1.1)
  3 mg/kg 479.2 ± 65.8 435.7 ± 74.4 −9.2 (−17.9 to −0.5)
  6 mg/kg 502.7 ± 71.1 442.2 ± 86.4 −12.5 (−18.0 to −7.0)
  1. aCI: confidence interval. Results are reported as means ± standard deviations. b-6 to −1 hours predosing.